I+D

I+D

I+D (2)

I+D (2)

I+D (3)

I+D (3)

I+D (4)

I+D (4)

rhEGF

Development of an innovative medicine based on human recombinant Epidermal Growth Factor (rhEGF), and its manufacturing processes, to have facilities authorised for the eco-efficient manufacture of the medicinal product developed for the treatment of severe diabetic foot ulcers.


Praxis's pioneering and most advanced project is PX070101, a new epidermal growth factor formulation, which is indicated for improving the healing process in chronic diabetic foot ulcers meeting severity criteria, either due to their extent or their depth.

Imagen6 eu

It is important to highlight that diabetic foot ulcers constitute a social-health problem of the first order. Firstly, it affects a significant number of patients, given the high prevalence of diabetes (approximately 7.5% of the Spanish population), and it is estimated that 15% of diabetics will have an ulcer on their extremity at some time in their lives. Moreover, this disease has a very negative effect on the quality of life of patients who suffer from it, not only on the physical and health spheres, but on the psychological, occupational and social spheres as well. Furthermore, the presence of an ulcer on the limb presents a risk for serious complications, which may even be life-threatening, and which often require amputation of the limb as the only therapeutic option.

 

PX070101 has already been registered in Colombia. It is in the clinical development phase in the European Union (EMA), and could be available on the European market in the next few years.

 


Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continúa navegando, consideramos que acepta su uso. Puede obtener más información, o bien conocer cómo cambiar la configuración, en nuestro enlace Políticas de Seguridad. We use our own cookies and third-party cookies to improve our services and show related advertising to your preferences by analyzing their browsing habits. If you continue to browse, consider accepting its use. You can get more information, or how to change the settings in our Política de privacidad.